Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07362459
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
A Phase III, Randomized, Double-blind, Multicenter Clinical Study to Evaluate the Efficacy and Safety of SCTB14 Versus Pembrolizumab as First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: Sinocelltech Ltd.
Conditions
Non-Small Cell Lung Carcinoma (NSCLC)
Interventions
Pembrolizumab SCTB14
Updated 1 time since 2026 Last updated: Jan 15, 2026 Started: Dec 30, 2025 Primary completion: Jul 31, 2027 Completion: Sep 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE3 trial investigates Non-Small Cell Lung Carcinoma (NSCLC) and is currently actively recruiting participants. Sinocelltech Ltd. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sinocelltech Ltd.
Data source: Sinocelltech Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .